Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sorrento In-Licenses Four China Biobetter/Biosimilars

publication date: Aug 3, 2015
Sorrento Therapeutics of San Diego in-licensed four monoclonal antibodies from Mabtech Limited, a holding company for China mAb biopharmas. All four of the mAbs have completed Phase III trials in China; two of them have filed for marketing approval. Sorrento will have rights to the mAbs in the US, Europe and Japan. Mabtech is owned by CDH Investments, an Asian private equity fund with more than $10 billion under management. No financials details were disclosed, nor did the release identify the companies that developed the molecules. More details....

Stock Symbol: (NDNQ: SRNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital